- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.04. | Elicera Therapeutics publishes the annual report for 2023 | 1 | Cision News | ||
| 04.04. | Nasdaq Stockholm AB: New equity right for trading, Elicera Therapeutics AB TO2 | 202 | GlobeNewswire | At the request of Elicera Therapeutics AB, Elicera Therapeutics AB equity
rights will be traded on First North Growth Market as from April 5, 2024.
Security name: Elicera Therapeutics AB TO2
-------------------------------------------
Short... ► Artikel lesen | |
| 28.03. | ELICERA THERAPEUTICS: Nomination committee proposes CMC specialist to Elicera's board of directors | 1 | Cision News | ||
| 27.03. | Nasdaq Stockholm AB: Last day of trading in paid subscription shares (BTU) of Elicera Therapeutics AB | 199 | GlobeNewswire | Trading in Elicera Therapeutics AB paid subscription units is to cease. The
last trading day is March 28, 2024.
Short name: ELIC BTU
ISIN code: SE0021626306
Orderbook ID: 324876
This information... ► Artikel lesen | |
| 11.03. | Elicera Therapeutics announces outcome in rights issue | 4 | Cision News | ||
| 07.03. | ELICERA THERAPEUTICS: Elicera collaborates with US cancer centre to evaluate iTANK | 2 | Cision News | ||
| 04.03. | Elicera Therapeutics receives additional subscription commitments from the board and management in the ongoing rights issue | 3 | Cision News | ||
| 23.02. | Nasdaq Stockholm AB: Listing of unit rights and paid subscription units of Elicera Therapeutics AB (91/24) | 445 | GlobeNewswire | With effect from February 26, 2024, the unit rights in Elicera Therapeutics AB
will be traded on First North Growth Market. Trading will continue up until and
including March 05, 2024.
Instrument:... ► Artikel lesen | |
| 23.02. | The subscription period in Elicera Therapeutics' rights issue of units starts today | 3 | Cision News | ||
| 21.02. | Elicera Therapeutics publishes prospectus in connection with rights issue of units | 1 | Cision News | ||
| 19.02. | ELICERA THERAPEUTICS: Full speed ahead for Elicera in 2024 | 3 | Cision News | ||
| 19.02. | XFRA CAPITAL ADJUSTMENT INFORMATION - 19.02.2024 | 676 | Xetra Newsboard | Das Instrument CP6 US2166484020 COOPER COS INC. DL-,10 EQUITY wird cum Kapitalmassnahme gehandelt am 19.02.2024 und ex Kapitalmassnahme am 20.02.2024 The instrument CP6 US2166484020 COOPER COS INC.... ► Artikel lesen | |
| 16.02. | Elicera Therapeutics' abstract on the iTANK platform's potential to enhance CAR T-cell treatment of solid tumors accepted for presentation at ISCT 2024 | 2 | Cision News | ||
| 16.02. | ELICERA THERAPEUTICS: Elicera invites to investor meetings on February 28[th] and 29[th] 2024 | 1 | Cision News | ||
| 14.02. | ELICERA THERAPEUTICS: Elicera gets green light for CAR T clinical study | 2 | Cision News | ||
| 13.02. | Elicera Therapeutics AB: Year-End Report 1 January - 31 December 2023 | 136 | GlobeNewswire (Europe) | Fourth quarter (October-December 2023)
Operating profit/loss amounted to SEK -5,212,694 (-3,951,799).
Loss for the period amounted to SEK -4,749,222 (-3,898,340).
Cash flow from operating... ► Artikel lesen | |
| 09.02. | LET EM KNOW AB: Elicera Therapeutics receives approval to initiate clinical Phase I/II-study CARMA with CAR T-cell therapy ELC-301 in B-Cell lymphoma | 1 | Cision News | ||
| 09.02. | Elicera Therapeutics receives approval to initiate clinical Phase I/II-study CARMA with CAR T-cell therapy ELC-301 in B-Cell lymphoma | - | Cision News | ||
| 18.01. | ELICERA THERAPEUTICS: Elicera's Board of Directors proposes a rights issue of units of approximately SEK 64 million | 2 | Cision News | ||
| 17.01. | Elicera Therapeutics' co-founder Magnus Essand invited to present the company's CAR T-cell projects at the world's largest cancer immunotherapy conference, CICON | 1 | Cision News |
Seite:
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 9,760 | -1,36 % | Evotec, Vidac Pharma, BioNTech - das Milliardenrennen um die Krebstherapie | Die Onkologie steht an der Schwelle zu einer goldenen Ära. Getrieben von einer Zunahme der Krebserkrankungen und beeindruckenden wissenschaftlichen Fortschritten, darunter Gen- und Immuntherapien, eröffnet... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 879,20 | -1,12 % | Regeneron Pharmaceuticals Q1 Profit Decreases, misses estimates | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals (REGN) reported a profit for first quarter that decreased from the same period last year and missed the Street estimates.The company's earnings... ► Artikel lesen | |
| BRAIN BIOTECH | 2,780 | -1,42 % | EQS-News: BRAIN Biotech AG unternimmt nächsten Schritt zur Optimierung der Gruppenstruktur | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Sonstiges
BRAIN Biotech AG unternimmt nächsten Schritt zur Optimierung der Gruppenstruktur
16.04.2024 / 11:20 CET/CEST
Für... ► Artikel lesen | |
| SCORPIUS | 0,175 | +1,16 % | Scorpius Holdings, Inc.: Scorpius Holdings Provides 2023 Year-End Business Update; Reports 570% Sequential Increase in Revenue for the Fourth Quarter of 2023 | DURHAM, N.C., April 29, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ('Scorpius" or "the Company"), an integrated contract development and manufacturing organization providing... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,808 | -2,80 % | Impulse setzen - Cardiol Therapeutics, Evotec, Redcare Pharmacy Aktie | Für risikobewusste Anleger ist die Pharma- und Biotechsparte ein lukrativer Markt für Investitionen. Die Branche wächst seit Jahrzehnten und auch für die kommenden Jahre wird mit einem Wachstum von... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 0,197 | -3,68 % | Burcon NutraScience Corporation: HPS and Burcon Achieve First Commercial Sales of World's First Hemp Protein Isolate | Vancouver, British Columbia--(Newsfile Corp. - April 29, 2024) - Burcon NutraScience Corporation (TSX: BU) ("Burcon" or the "Company"), a global technology leader in the development of plant-based... ► Artikel lesen | |
| CSL | 170,02 | -0,19 % | CSL: Real-World Evidence Study Proves Effectiveness Of Cell-Based Quadrivalent Influenza Vaccines | CANBERA (dpa-AFX) - CSL Seqirus, a subsidiary of CSL Ltd. (CSL.AX), Thursday said that a real-world evidence study shows that a cell-based quadrivalent influenza vaccine has been more effective... ► Artikel lesen | |
| MANNKIND | 4,094 | +0,27 % | MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases | First-in-human study to evaluate safety, tolerability and pharmacokinetics (PK) in healthy volunteersEnrollment of first study participant anticipated in June 2024 DANBURY, Conn. and WESTLAKE VILLAGE... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 5,818 | +1,57 % | Ocular Therapeutix, Inc.: Ocular Therapeutix To Present at Two Ophthalmology Meetings, May 4-9, 2024 | ||
| OXFORD NANOPORE TECHNOLOGIES | 1,314 | -1,20 % | Oxford Nanopore Tech - Issue of Equity and Total Voting Rights | ||
| CODEXIS | 3,640 | -0,16 % | Earnings call: Codexis posts strong Q1 2024 results, expands RNA solutions | ||
| ADAPTIMMUNE THERAPEUTICS | 1,120 | 0,00 % | Adaptimmune Therapeutics PLC: Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024 | Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 1, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell... ► Artikel lesen | |
| BIORA THERAPEUTICS | 0,670 | -2,19 % | Biora Therapeutics, Inc.: Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap Platform Development | All pharmacokinetic endpoints were achieved, with a PK profile consistent with drug delivery and absorption in the colon All NaviCap devices performed as intended and were well tolerated, with... ► Artikel lesen | |
| TELO GENOMICS | 0,063 | -25,00 % | Telo Genomics Corp.: Telo Genomics Receives Accreditation from College of American Pathologists | Toronto, Ontario--(Newsfile Corp. - April 10, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology... ► Artikel lesen | |
| CORMEDIX | 5,200 | -4,59 % | CorMedix, Inc.: CorMedix Inc. Announces CMS Grants TDAPA to DefenCath | BERKELEY HEIGHTS, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening... ► Artikel lesen |
Das Unternehmen ELICERA THERAPEUTICS AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,062 Euro und damit -2,84 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
